# NST003 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nst003

> NST003, sponsored by NeuroSense Therapeutics Ltd. (NRSN): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | NST003 |
| Codes | NST003 |
| Sponsor | NeuroSense Therapeutics Ltd. (NRSN) https://sec-api.dev/companies/nrsn/catalysts |
| Indications | als, reporting |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2023: topline data readout

- Status: completed, met. Date confidence: month. Stage: 2. Indication: ALS, reporting.
- First seen 2024-11-19, last confirmed 2026-09-25.
- SEC Form 10-K (accession 0001213900-25-029464): "In December 2023, we announced topline clinical efficacy results in our Phase 2b PARADIGM (NST003) trial of PrimeC for the treatment of ALS, reporting that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints." https://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-103534): "In December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM." https://www.sec.gov/Archives/edgar/data/1875091/000121390026103534/ea030656401ex99-3.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-070315): "December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM." https://www.sec.gov/Archives/edgar/data/1875091/000121390025070315/ea025084301ex99-3_neurosense.htm
- SEC Form 10-K (accession 0001213900-26-036970): "In December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM." https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/ea0283072-20f_neurosense.htm
- SEC Form 10-K (accession 0001213900-25-029464): "December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM." https://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm
- SEC registration statement (S-1) (accession 0001213900-24-100165): "In December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM." https://www.sec.gov/Archives/edgar/data/1875091/000121390024100165/ea0221577-f1_neuro.htm
- SEC Form 10-K (accession 0001213900-26-036970): "December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our Phase 2b trial." https://www.sec.gov/Archives/edgar/data/1875091/000121390026036970/ea0283072-20f_neurosense.htm
- SEC Form 10-K (accession 0001213900-25-029464): "In December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our Phase 2b trial." https://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nst003.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NST003 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nst003

```bibtex
@misc{secapidev_pdufa_nst003_20261116,
  title        = {NST003 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nst003}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nst003_20261116","title":"NST003 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nst003","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
